Triple-negative breast cancer (TNBC) is an aggressive BC subtype accounting for 10–20% of all BC cases and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This evidence concerns the gene ESR1 and breast cancer.